Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merrimack Pharmaceuticals, Inc. - Common Stock (NQ: MACK )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merrimack Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 Next >
MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q1 2024
Merrimack Pharmaceuticals just reported results for the first quarter of 2024. 
Via InvestorPlace
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Merrimack Receives $225 Million Milestone Payment from Ipsen
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) Highlighted for Surprising Price Action
Via Investor Brand Network
MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023
Merrimack Pharmaceuticals just reported results for the fourth quarter of 2023. 
Via InvestorPlace
Merrimack Reports Full Year 2023 Financial Results
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
$2M Bet On Ford? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Monday, there were a few notable insider trades. 
Via Benzinga
Merrimack Reports Third Quarter 2023 Financial Results
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Pancreatic Cancer Battle Boosted by $200M VC Firm
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:MACK),(NASDAQ:INCY),(NASDAQ:MRTX),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death
Merrimack Reports Second Quarter 2023 Financial Results
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Merrimack Reports First Quarter 2023 Financial Results
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Why Jounce Therapeutics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're beginning the day with a look at the biggest pre-market stock movers traders need to know about for Wednesday morning! 
Via InvestorPlace
Luna Innovations, Guess? And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Merrimack Reports Full Year 2022 Financial Results
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
3 Stocks Insiders Are Buying: Triumph Financial And More
Although US stocks closed higher on Tuesday, there were a few notable insider trades. 
Via Benzinga
$2.6M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed mostly lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
Insiders Buying Heska, B. Riley Financial And 2 Other Stocks
Although US stocks closed mixed on Monday, there were a few notable insider trades. 
Via Benzinga
$1.4 Million Bet On Joint Corp? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 15, 2022 – USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French biotech... 
Via FinancialNewsMedia
Topics Death
Exposures Death
Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MACK),(NASDAQ:NRBO),(NYSE:MRK),(NASDAQ:RNAZ), EQNX::TICKER_END 
Via FinancialNewsMedia
Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Nasdaq Drops 200 Points; Meta Platforms Shares Jump
U.S. stocks traded lower toward the end of trading , with the Nasdaq Composite dropping 200 points on Wednesday. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers 
Via Benzinga
Crude Oil Down Over 2%; Outset Medical Shares Spike Higher
U.S. stocks traded lower midway through trading as investors focused on the outcome of the midterm elections. 
Via Benzinga
Why RumbleON Shares Are Trading Higher By Around 28%? Here Are 84 Stocks Moving In Wednesday's Mid-Day Session
Gainers 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS